The 5 most recent market catalysts affecting $WVE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Bearish
Impact 85
Wave Life Sciences shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral rating. The company also announced the initiation of its Phase 2a clinical trial evaluating WVE-007 in combination with tirzepatide in adults living with obesity.
The primary driver of the stock's movement is the JP Morgan downgrade from Overweight to Neutral. This signals a loss of confidence from a significant institutional investor, often…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 55
Mizuho Maintains Outperform on WAVE Life Sciences, Lowers Price Target to $23
Mizuho analyst Salim Syed maintained an 'Outperform' rating for WAVE Life Sciences, signaling continued confidence in the company's long-term prospects. However, the reduction of t…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 55
Wedbush Maintains Outperform on WAVE Life Sciences, Lowers Price Target to $12
Wedbush analyst Yun Zhong reiterated an 'Outperform' rating for WAVE Life Sciences (WVE) but simultaneously reduced the price target from $15 to $12. This action signals that while…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 95
WAVE Life Sciences Q2 EPS $(0.34) Misses $(0.31) Estimate, Sales $2.272M Miss $7.050M Estimate
WAVE Life Sciences announced Q2 earnings per share of $(0.34), missing the $(0.31) estimate by 9.68%, and sales of $2.272 million, missing the $7.050 million estimate by a substant…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.